---
schema_version: "secwatch.filing_event.v1"
accession: "0001828185-24-000089"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2024-11-15T23:59:59+00:00"
generated_at: "2026-05-29T23:52:12.572475+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Barinthus/Arbutus HBV data: 23% HBsAg loss with nivolumab; 2 functional cures in Phase 2b

## Summary
- IM-PROVE II Group C: 23% (3/13) on imdusiran + VTP-300 + low-dose nivolumab achieved HBsAg loss by Week 48.
- HBV003: 8 participants achieved HBsAg loss; 2 met functional cure criteria; 2 seroconverted to HBsAb.
- In HBV003, 66% (6/9) who discontinued NUCs remained off therapy >6 months, 2 meeting functional cure.
- Both regimens were generally well tolerated with no treatment-related SAEs reported.

## SEC filing metadata
- accession: 0001828185-24-000089
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2024-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000089/0001828185-24-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000089/brns-20241115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001828185-24-000089
- JSON: https://secwatch.observer/filing/0001828185-24-000089.json
- Plain text: https://secwatch.observer/filing/0001828185-24-000089.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.